Filtering by:
Non-Hodgkin LymphomaSlideshow: COVID-19 Pandemic Affects the Cancer Continuum
ACS 2021 studies show how COVID-19 is affecting prevention efforts, expected cancer screening rates, treatment, quality-of-life, and research.
Non-Hodgkin Lymphoma Survivor Copes With Coronavirus Pandemic
Phyllis Alsterberg was recently treated for non-Hodgkin lymphoma. She hasn’t left her home in New York City much since the coronavirus outbreak started because she has a weakened immune system and she’s worried about getting sick.
Study: Getting Enough Exercise Lowers Risk of 7 Cancers
Getting recommended amounts of physical activity is linked to a lower risk for 7 cancer types, according to a study from the American Cancer Society, the National Cancer Institute, and the Harvard T.H. Chan School of Public Health.
Lymphoma Survivor Becomes Nurse to Help Cancer Patients
When Crystal Zunino was diagnosed with non-Hodgkin lymphoma in January 2015, she was just half-way through her first year as a new middle-school math teacher in Warner Robins, Georgia.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
FDA Approves First Biosimilar for Non-Hodgkin Lymphoma
The US Food and Drug Administration (FDA) has approved Truxima (rituximab-abbs), the first biosimilar drug to treat adults with some types of non-Hodgkin lymphoma.
A Pioneer in Developing Drugs for People with T-Cell Lymphoma
Owen A. O'Connor, MD, PhD, was awarded the prestigious American Cancer Society Clinical Research Professor grant in July 2018. He was selected because of his expertise and ongoing work to develop drugs to improve treatments for people with Hodgkin and non-Hodgkin lymphomas. He's a professor and researcher at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center in New York, New York.
FDA Approves Poteligeo (Mogamulizumab) for Lymphoma of the Skin
The US Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab) to treat people with some types of skin lymphoma.